Active Biotech to Present at the UBS Global Life Sciences Conference

September 17, 2009 14:00 (CEST)
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to -
The presentation will take place on September 22, at 2:00 pm US Eastern Time / 20:00 Central European Time
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 2:00 pm CET on September 17, 2009.
Active Biotech AB                                        
Göran Forsberg, VP Investor Relations & Business Development           
P.O. Box 724, SE-220 07 Lund, Sweden            
Tel: +46 (0)46-19 20 00                                     
Fax: +46 (0)46-19 11 00